PUMA BIOTECHNOLOGY, INC. (PBYI) Operating Margin
- Operating margin · 12 months: Value 13.16%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 13.16% | Operating income / revenue. Period ending 2026-06-30. $30.44M ÷ $231.24M × 100 ≈ 13.16% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 30.44M USD | Operating Income (Loss) |
| Revenue | 231.24M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 58.20M USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 71.17M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $30.44M | $231.24M | $58.20M | (m) | $71.17M | 13.16% |
| 2026-03-31 | $29.49M | $227.18M | $58.02M | (m) | $71.67M | 12.98% |
| 2025-12-31 | $37.30M | $228.37M | $58.16M | (m) | $70.85M | 16.33% |
| 2025-09-30 | $33.56M | $212.00M | $48.95M | (m) | $69.09M | 15.83% |
| 2025-06-30 | $46.06M | $238.06M | $65.88M | (m) | $69.09M | 19.35% |
| 2025-03-31 | $37.25M | $232.71M | $64.23M | (m) | $76.02M | 16.01% |
| 2024-12-31 | $30.97M | $230.47M | $64.40M | (m) | $80.16M | 13.44% |
| 2024-09-30 | $32.40M | $243.57M | $74.81M | (m) | $83.72M | 13.30% |
| 2024-06-30 | $18.91M | $219.14M | $58.99M | (m) | $89.71M | 8.63% |
| 2024-03-31 | $25.98M | $226.63M | $60.19M | (m) | $89.20M | 11.46% |
| 2023-12-31 | $32.64M | $235.64M | $62.68M | (m) | $89.93M | 13.85% |
| 2023-09-30 | $27.86M | $229.13M | $55.20M | (m) | $94.79M | 12.16% |
| 2023-06-30 | $21.67M | $230.12M | $54.41M | (m) | $95.95M | 9.42% |
| 2023-03-31 | $28.83M | $235.07M | $57.47M | (m) | $92.06M | 12.27% |
| 2022-12-31 | $23.72M | $228.03M | $55.09M | (m) | $89.98M | 10.40% |
| 2022-09-30 | $20.54M | $217.71M | $50.15M | (m) | $87.40M | 9.43% |
| 2022-06-30 | $9.19M | $206.86M | $47.94M | $60.21M | $89.52M | 4.44% |
| 2022-03-31 | $-19.60M | $200.72M | $44.99M | $66.88M | $108.46M | -9.77% |
| 2021-12-31 | $1.29M | $253.16M | $63.70M | $71.87M | $116.29M | 0.51% |
| 2021-09-30 | $-16.69M | $250.35M | (m) | $81.86M | $122.44M | -6.67% |
| 2021-06-30 | $-19.87M | $254.86M | (m) | $86.37M | $125.95M | -7.80% |
| 2021-03-31 | $4.00M | $272.06M | (m) | $92.42M | $115.79M | 1.47% |
| 2020-12-31 | $-30.40M | $225.11M | (m) | $97.65M | $118.49M | -13.51% |
| 2020-09-30 | $-27.97M | $235.47M | (m) | $103.73M | $121.14M | -11.88% |
| 2020-06-30 | $-30.29M | $241.07M | (m) | $110.41M | $122.94M | -12.56% |
| 2020-03-31 | $-63.20M | $224.41M | (m) | $122.58M | $127.12M | -28.16% |
| 2019-12-31 | $-39.10M | $272.26M | (m) | $132.85M | $141.69M | -14.36% |
| 2019-09-30 | $-48.93M | $280.42M | (m) | $140.94M | $151.38M | -17.45% |
| 2019-06-30 | $-45.77M | $286.69M | $36.71M | $147.27M | $148.48M | -15.96% |
| 2019-03-31 | $-61.43M | $283.54M | $36.22M | $153.66M | $155.09M | -21.67% |
| 2018-12-31 | $-94.67M | $250.99M | $34.62M | $164.85M | $146.19M | -37.72% |
| 2018-09-30 | $-139.68M | $201.52M | (m) | $176.78M | $136.11M | -69.32% |
| 2018-06-30 | $-205.84M | $144.97M | (m) | $189.93M | $140.10M | -141.99% |
| 2018-03-31 | $-242.58M | (m) | (m) | $199.93M | $124.89M | (m) |
| 2017-12-31 | $-292.39M | $27.68M | (m) | $207.81M | $106.69M | -1056.13% |
| 2017-09-30 | $-301.69M | (m) | (m) | $213.95M | (m) | (m) |
| 2017-06-30 | $-290.25M | (m) | (m) | $216.43M | (m) | (m) |
| 2017-03-31 | $-278.55M | (m) | (m) | $217.39M | (m) | (m) |
| 2016-12-31 | $-276.60M | (m) | (m) | $222.80M | (m) | (m) |
| 2016-09-30 | $-265.76M | (m) | (m) | $218.84M | (m) | (m) |
| 2016-06-30 | $-260.50M | (m) | (m) | $218.79M | (m) | (m) |
| 2016-03-31 | $-258.93M | (m) | (m) | $223.95M | (m) | (m) |
| 2015-12-31 | $-240.28M | (m) | (m) | $208.47M | (m) | (m) |
| 2015-09-30 | $-225.84M | (m) | (m) | $195.56M | (m) | (m) |
| 2015-06-30 | $-201.06M | (m) | (m) | $175.73M | (m) | (m) |
| 2015-03-31 | $-175.06M | (m) | (m) | $151.35M | (m) | (m) |
| 2014-12-31 | $-142.28M | (m) | (m) | $122.92M | (m) | (m) |
| 2014-09-30 | $-110.67M | (m) | (m) | $96.39M | (m) | (m) |
| 2014-06-30 | $-89.04M | (m) | (m) | $76.37M | (m) | (m) |
| 2014-03-31 | $-62.85M | (m) | (m) | $51.81M | (m) | (m) |
| 2013-12-31 | $-54.83M | (m) | (m) | $45.05M | (m) | (m) |
| 2013-09-30 | $-60.79M | (m) | (m) | $40.32M | (m) | (m) |
| 2013-06-30 | $-72.33M | (m) | (m) | $46.03M | (m) | (m) |
| 2013-03-31 | $-74.40M | (m) | (m) | $48.60M | (m) | (m) |
| 2012-12-31 | $-74.45M | (m) | (m) | $49.64M | (m) | (m) |
| 2012-09-30 | $-62.29M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $-36.75M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $-22.00M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-10.16M | (m) | (m) | $826.37K | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |